			Home About us Contact

Psychopharmacology

Distribution by Scientific Domains

Medical Sciences	80%
Psychology	17%

Distribution within Medical Sciences

Psychiatry	80%
Pharmacology & Pharmaceutical Medicine	5%
5 Other Subdomains	15%

Selected Abstracts

Current Awareness in Human Psychopharmacology

HUMAN PSYCHOPHARMACOLOGY: CLINICAL AND EXPERIMENTAL, Issue 4 2003
Article first published online: 19 MAY 200
In order to keep subscribers up-to-date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliography contains newly published material in the field of human psychopharmacology. Each bibliography is divided into 18 sections: 1 Books, Reviews & Symposia; 2 General; 3 Psychotropic Drugs - General; Antidepressive Agents: 4 Tricyclics; 5 Monoamine Oxidase Inhibitors; 6 Serotonergics; Euthymic Agents: 7 Lithium; Tranquillizing Agents: 8 Major; 9 Minor & Hypnotics; 10 Analeptic Agents; 11 Anticonvulsant Agents; 12 Drugs of Abuse; 13 Transmitters, Receptors, Metabolites & Modulating Agents; 14 Neuropeptides; 15 Psychoneuroendocrinology; 16 Psychoneuroimmunology; 17 Behavioural Genetics; 18 Others. Within each section, articles are listed in alphabetical order with respect to author. If, in the preceding period, no publications are located relevant to any one of these headings, that section will be omitted. [source]

Current Awareness in Human Psychopharmacology

HUMAN PSYCHOPHARMACOLOGY: CLINICAL AND EXPERIMENTAL, Issue 7 2002
Article first published online: 24 SEP 200
In order to keep subscribers up-to-date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliography contains newly published material in the field of human psychopharmacology. Each bibliography is divided into 18 sections: 1 Books, Reviews & Symposia; 2 General; 3 Psychotropic Drugs - General; Antidepressive Agents: 4 Tricyclics; 5 Monoamine Oxidase Inhibitors; 6 Serotonergics; Euthymic Agents: 7 Lithium; Tranquillizing Agents: 8 Major; 9 Minor & Hypnotics; 10 Analeptic Agents; 11 Anticonvulsant Agents; 12 Drugs of Abuse; 13 Transmitters, Receptors, Metabolites & Modulating Agents; 14 Neuropeptides; 15 Psychoneuroendocrinology; 16 Psychoneuroimmunology; 17 Behavioural Genetics; 18 Others. Within each section, articles are listed in alphabetical order with respect to author. If, in the preceding period, no publications are located relevant to any one of these headings, that section will be omitted. [source]

Evolution of concepts, development of treatment and growth of concern

PROGRESS IN NEUROLOGY AND PSYCHIATRY, Issue 8 2008
Professor Malcolm Lader
The diagnostic criteria for anxiety disorders have changed markedly over the past 50 years and continue to evolve. However, Professor Malcolm Lader, Emeritus Professor of Clinical Psychopharmacology, King's College London, argued in his Keynote Lecture at the Latest Advances in Psychiatry Symposium earlier in the year, that these changes might reflect less conceptual and pathophysiological developments and more perceived treatability. Medical writer, Mark Greener, reports. Copyright © 2008 Wiley Interface Ltd [source]

Psychopharmacology: concepts and opinions about the use of stimulant medications

THE JOURNAL OF CHILD PSYCHOLOGY AND PSYCHIATRY AND ALLIED DISCIPLINES, Issue 1-2 2009
James M. Swanson
First page of article [source]

Practitioner Review: Psychopharmacology in children and adolescents with mental retardation

THE JOURNAL OF CHILD PSYCHOLOGY AND PSYCHIATRY AND ALLIED DISCIPLINES, Issue 9 2006
Benjamin L. Handen
Background:, The use of psychotropic medication to treat children and adults with mental retardation (MR) has a long and extensive history. There are no identified medications to address specific cognitive deficits among persons with MR. Instead, psychotropic medications are used to treat specific behavioral symptoms and/or psychiatric syndromes. The purpose of this review is to provide an overview of the recent literature regarding the use of psychotropic medications in this population, focusing primarily on children and adolescents. Methods:, The paper is divided into five general drug categories: psychostimulants, antipsychotics, antidepressants, mood stabilizers, and other drugs. Each section offers an overview of the research supporting the use of that class of medications in children and adolescents with MR as well as cautions regarding potential side effects. Finally, specific clinical recommendations are offered. Results:, The majority of studies in MR tend to be open trials, case reports, or controlled studies with small samples. The available data suggests that persons with MR respond to various psychotropic medications in ways similar to the typically developing population. However, rates of response tend to be poorer and the occurrence of side effects tends to be more frequent. Conclusions:, The use of psychotropic medications in children and adolescents with MR requires even greater monitoring and the use of lower doses and slower dosage increases than in the general population. [source]

Psychopharmacology of substance misuse and comorbid psychiatric disorders

ACTA NEUROPSYCHIATRICA, Issue 1 2004
M. T. Abou-Saleh
The common occurrence of comorbid substance misuse and other psychiatric disorders has challenged the diagnostic and therapeutic skills of professionals concerned with the care of patients with these dual disorders. Combined pharmacological and psychological treatment approaches have evolved empirically drawing upon standard treatments with emphasis on psychosocial approaches to substance misuse for psychotic disorders and pharmacological approaches for mood disorders. Advances in the biology of both disorders have started to inform their psychopharmacology. The specific role of atypical antipscychotics is highlighted. Further studies of the biology of comorbidity will impact the use of effective pharmaceuticals such as clozapine with dual effects on schizophrenia and substance misuse. [source]

Applied psychometrics in clinical psychiatry: the pharmacopsychometric triangle

ACTA PSYCHIATRICA SCANDINAVICA, Issue 5 2009
P. Bech
Objective:, To consider applied psychometrics in psychiatry as a discipline focusing on pharmacopsychology rather than psychopharmacology as illustrated by the pharmacopsychometric triangle. Method:, The pharmacopsychological dimensions of clinically valid effects of drugs (antianxiety, antidepressive, antimanic, and antipsychotic), of clinically unwanted effects of these drugs, and the patients' own subjective perception of the balance between wanted and unwanted effects are analysed using rating scales assessed by modern psychometric tests (item response theory models) Results:, Symptom rating scales fulfilling the item response theory models have been shown to be psychometrically valid outcome scales as their total scores are sufficient statistics for demonstrating dose,response relationship within the various classes of antianxiety, antidepressive, antimanic or antipsychotic drugs. The total scores of side-effect rating scales are, however, not sufficient statistics, implying that each symptom has to be analysed individually. Self-rating scales with very few items appear to be sufficient statistics when measuring the patients' own perception of quality of life. Conclusion:, Applied psychometrics in psychiatry have been found to cover a pharmacopsychometric triangle illustrating the measurements of wanted and unwanted effects of pharmacotherapeutic drugs as well as health-related quality of life. [source]

Conversation with Murray Jarvik

ADDICTION, Issue 9 2001
Article first published online: 1 SEP 200
In this occasional series we record the views and personal experience of people who have specially contributed to the evolution of ideas in the Journal's field of interest. Murray Jarvik's long and fruitful career in research and teaching spans the 50-year period beginning before the explosion of interest in psychopharmacology up to the present. His studies on LSD, among the first ever published, were followed by studies on the effects of drugs on memory and memory consolidation, which were then followed by studies on nicotine, smoking and pharmacological interventions in tobacco dependence. His contributions to the field of tobacco dependence have earned him international recognition. [source]

5-HT1B receptor knockout mice show a compensatory reduction in 5-HT2C receptor function

EUROPEAN JOURNAL OF NEUROSCIENCE, Issue 1 2003
Peter G. Clifton
Abstract Although null mutant (,knockout') mice have provided valuable animal models to complement traditional approaches to psychopharmacology, such animals may also show complex adaptations to the induced mutation. Here we demonstrate that serotonin1B (5-HT1B) receptor knockout (KO) mice show adaptations in serotonin2C (5-HT2C) receptor-mediated functions. They show smaller reductions in food intake and locomotor activity in response to administration of 5-HT2C receptor agonists that are not accounted for by altered drug disposition. These effects are not mimicked by pretreatment of wildtype (WT) mice with a 5-HT1B receptor antagonist showing that they result from a longer term adaptation to the loss of 5-HT1B receptor function and not from a short-term interaction between 5-HT1B - and 5-HT2C -mediated functions. In addition, we show that 5-HT1B receptor KO mice have a lowered hypothalamic c-fos response to the administration of 5-HT2C receptor agonists. These results demonstrate that compensatory adaptations to the constitutive loss of 5-HT1B receptors may be an important determinant of the altered response of 5-HT1B KO mice to a variety of pharmacological challenges. [source]

What is reinforcement sensitivity?

EUROPEAN JOURNAL OF PERSONALITY, Issue 5 2008
Neuroscience paradigms for approach-avoidance process theories of personality
Abstract Reinforcement sensitivity is a concept proposed by Gray (1973) to describe the biological antecedents of personality, and has become the common mechanism among a family of personality theories concerning approach and avoidance processes. These theories suggest that 2,3 biobehavioural systems mediate the effects of reward and punishment on emotion and motivation, and that individual differences in the functioning of these systems manifest as personality. Identifying paradigms for operationalising reinforcement sensitivity is therefore critical for testing and developing these theories, and evaluating their footprint in personality space. In this paper I suggest that, while traditional self-report paradigms in personality psychology may be less-than-ideal for this purpose, neuroscience paradigms may offer operations of reinforcement sensitivity at multiple levels of approach and avoidance processes. After brief reflection on the use of such methods in animal models,which first spawned the concept of reinforcement sensitivity,recent developments in four domains of neuroscience are reviewed. These are psychogenomics, psychopharmacology, neuroimaging and category-learning. By exploring these paradigms as potential operations of reinforcement sensitivity we may enrich our understanding of the putative biobehavioural bases of personality. Copyright © 2008 John Wiley & Sons, Ltd. [source]

Current awareness in human psychopharmacology

HUMAN PSYCHOPHARMACOLOGY: CLINICAL AND EXPERIMENTAL, Issue 5 2010
Article first published online: 29 JUN 2010
In order to keep subscribers up-to-date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliography contains newly published material in the field of human psychopharmacology. Each bibliography is divided into 18 sections: 1 Reviews; 2 General; 3 Psychotropic Drugs - General; Antidepressive Agents: 4 Tricyclics; 5 Monoamine Oxidase Inhibitors; 6 Serotonergics; Euthymic Agents: 7 Lithium; Tranquillizing Agents: 8 Major; 9 Minor & Hypnotics; 10 Analeptic Agents; 11 Anticonvulsant Agents; 12 Drugs of Abuse; 13 Transmitters, Receptors, Metabolites & Modulating Agents; 14 Neuropeptides; 15 Psychoneuroendocrinology; 16 Psychoneuroimmunology; 17 Behavioural Genetics; 18 Others. Within each section, articles are listed in alphabetical order with respect to author. If, in the preceding period, no publications are located relevant to any one of these headings, that section will be omitted. [source]

Current awareness in human psychopharmacology

HUMAN PSYCHOPHARMACOLOGY: CLINICAL AND EXPERIMENTAL, Issue 1 2010
Article first published online: 29 DEC 200
In order to keep subscribers up-to-date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliography contains newly published material in the field of human psychopharmacology. Each bibliography is divided into 18 sections: 1 Reviews; 2 General; 3 Psychotropic Drugs - General; Antidepressive Agents: 4 Tricyclics; 5 Monoamine Oxidase Inhibitors; 6 Serotonergics; Euthymic Agents: 7 Lithium; Tranquillizing Agents: 8 Major; 9 Minor & Hypnotics; 10 Analeptic Agents; 11 Anticonvulsant Agents; 12 Drugs of Abuse; 13 Transmitters, Receptors, Metabolites & Modulating Agents; 14 Neuropeptides; 15 Psychoneuroendocrinology; 16 Psychoneuroimmunology; 17 Behavioural Genetics; 18 Others. Within each section, articles are listed in alphabetical order with respect to author. If, in the preceding period, no publications are located relevant to any one of these headings, that section will be omitted. [source]

Current awareness in human psychopharmacology

HUMAN PSYCHOPHARMACOLOGY: CLINICAL AND EXPERIMENTAL, Issue 4 2008
Article first published online: 22 MAY 200
In order to keep subscribers up-to-date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliography contains newly published material in the field of human psychopharmacology. Each bibliography is divided into 18 sections: 1 Reviews; 2 General; 3 Psychotropic Drugs - General; Antidepressive Agents: 4 Tricyclics; 5 Monoamine Oxidase Inhibitors; 6 Serotonergics; Euthymic Agents: 7 Lithium; Tranquillizing Agents: 8 Major; 9 Minor & Hypnotics; 10 Analeptic Agents; 11 Anticonvulsant Agents; 12 Drugs of Abuse; 13 Transmitters, Receptors, Metabolites & Modulating Agents; 14 Neuropeptides; 15 Psychoneuroendocrinology; 16 Psychoneuroimmunology; 17 Behavioural Genetics; 18 Others. Within each section, articles are listed in alphabetical order with respect to author. If, in the preceding period, no publications are located relevant to any one of these headings, that section will be omitted. [source]

Current awareness in human psychopharmacology

HUMAN PSYCHOPHARMACOLOGY: CLINICAL AND EXPERIMENTAL, Issue 3 2008
Article first published online: 31 MAR 200
In order to keep subscribers up-to-date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliography contains newly published material in the field of human psychopharmacology. Each bibliography is divided into 18 sections: 1 Reviews; 2 General; 3 Psychotropic Drugs - General; Antidepressive Agents: 4 Tricyclics; 5 Monoamine Oxidase Inhibitors; 6 Serotonergics; Euthymic Agents: 7 Lithium; Tranquillizing Agents: 8 Major; 9 Minor & Hypnotics; 10 Analeptic Agents; 11 Anticonvulsant Agents; 12 Drugs of Abuse; 13 Transmitters, Receptors, Metabolites & Modulating Agents; 14 Neuropeptides; 15 Psychoneuroendocrinology; 16 Psychoneuroimmunology; 17 Behavioural Genetics; 18 Others. Within each section, articles are listed in alphabetical order with respect to author. If, in the preceding period, no publications are located relevant to any one of these headings, that section will be omitted. [source]

Current awareness in human psychopharmacology

HUMAN PSYCHOPHARMACOLOGY: CLINICAL AND EXPERIMENTAL, Issue 6 2007
Article first published online: 2 AUG 200
In order to keep subscribers up-to-date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliography contains newly published material in the field of human psychopharmacology. Each bibliography is divided into 18 sections: 1 Reviews; 2 General; 3 Psychotropic Drugs - General; Antidepressive Agents: 4 Tricyclics; 5 Monoamine Oxidase Inhibitors; 6 Serotonergics; Euthymic Agents: 7 Lithium; Tranquillizing Agents: 8 Major; 9 Minor & Hypnotics; 10 Analeptic Agents; 11 Anticonvulsant Agents; 12 Drugs of Abuse; 13 Transmitters, Receptors, Metabolites & Modulating Agents; 14 Neuropeptides; 15 Psychoneuroendocrinology; 16 Psychoneuroimmunology; 17 Behavioural Genetics; 18 Others. Within each section, articles are listed in alphabetical order with respect to author. If, in the preceding period, no publications are located relevant to any one of these headings, that section will be omitted. [source]

Current awareness in human psychopharmacology

HUMAN PSYCHOPHARMACOLOGY: CLINICAL AND EXPERIMENTAL, Issue 8 2006
Article first published online: 29 NOV 200
In order to keep subscribers up-to-date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliography contains newly published material in the field of human psychopharmacology. Each bibliography is divided into 18 sections: 1 Books, Reviews & Symposia; 2 General; 3 Psychotropic Drugs - General; Antidepressive Agents: 4 Tricyclics; 5 Monoamine Oxidase Inhibitors; 6 Serotonergics; Euthymic Agents: 7 Lithium; Tranquillizing Agents: 8 Major; 9 Minor & Hypnotics; 10 Analeptic Agents; 11 Anticonvulsant Agents; 12 Drugs of Abuse; 13 Transmitters, Receptors, Metabolites & Modulating Agents; 14 Neuropeptides; 15 Psychoneuroendocrinology; 16 Psychoneuroimmunology; 17 Behavioural Genetics; 18 Others. Within each section, articles are listed in alphabetical order with respect to author. If, in the preceding period, no publications are located relevant to any one of these headings, that section will be omitted. [source]

Current awareness in human psychopharmacology

HUMAN PSYCHOPHARMACOLOGY: CLINICAL AND EXPERIMENTAL, Issue 7 2006
Article first published online: 9 OCT 200
In order to keep subscribers up-to-date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliography contains newly published material in the field of human psychopharmacology. Each bibliography is divided into 18 sections: 1 Books, Reviews & Symposia; 2 General; 3 Psychotropic Drugs - General; Antidepressive Agents: 4 Tricyclics; 5 Monoamine Oxidase Inhibitors; 6 Serotonergics; Euthymic Agents: 7 Lithium; Tranquillizing Agents: 8 Major; 9 Minor & Hypnotics; 10 Analeptic Agents; 11 Anticonvulsant Agents; 12 Drugs of Abuse; 13 Transmitters, Receptors, Metabolites & Modulating Agents; 14 Neuropeptides; 15 Psychoneuroendocrinology; 16 Psychoneuroimmunology; 17 Behavioural Genetics; 18 Others. Within each section, articles are listed in alphabetical order with respect to author. If, in the preceding period, no publications are located relevant to any one of these headings, that section will be omitted. [source]

Current awareness in human psychopharmacology

HUMAN PSYCHOPHARMACOLOGY: CLINICAL AND EXPERIMENTAL, Issue 3 2005
Article first published online: 30 MAR 200
In order to keep subscribers up-to-date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliography contains newly published material in the field of human psychopharmacology. Each bibliography is divided into 18 sections: 1 Books, Reviews & Symposia; 2 General; 3 Psychotropic Drugs - General; Antidepressive Agents: 4 Tricyclics; 5 Monoamine Oxidase Inhibitors; 6 Serotonergics; Euthymic Agents: 7 Lithium; Tranquillizing Agents: 8 Major; 9 Minor & Hypnotics; 10 Analeptic Agents; 11 Anticonvulsant Agents; 12 Drugs of Abuse; 13 Transmitters, Receptors, Metabolites & Modulating Agents; 14 Neuropeptides; 15 Psychoneuroendocrinology; 16 Psychoneuroimmunology; 17 Behavioural Genetics; 18 Others. Within each section, articles are listed in alphabetical order with respect to author. If, in the preceding period, no publications are located relevant to any one of these headings, that section will be omitted. [source]

Current Awareness in Human Psychopharmacology

The therapeutic promise of single enantiomers: introduction

HUMAN PSYCHOPHARMACOLOGY: CLINICAL AND EXPERIMENTAL, Issue S2 2001
Irving W. Wainer
Abstract This review uses several examples drawn from the literature to show how using active enantiomers as therapeutic agents may yield several benefits, including more predictable pharmacokinetics, more accurate drug monitoring and enhanced tolerability. As a result of these benefits, the therapeutic use of single enantiomers will become increasingly important not only in psychopharmacology, but in medicine generally. Indeed, over the early years of the new millennium, the therapeutic use of single active enantiomers is set to redefine the benefit,risk ratio in the management of many common conditions. Copyright © 2001 John Wiley & Sons, Ltd. [source]

An introduction to enantiomers in psychopharmacology

HUMAN PSYCHOPHARMACOLOGY: CLINICAL AND EXPERIMENTAL, Issue S2 2001
Brian E. Leonard
Abstract There is growing scientific, clinical, commercial and regulatory recognition that enantiomers offer benefits over racemates in the management of psychiatric diseases as well as in clinical medicine generally. However, relatively few studies consider enantiomers' individual characteristics. This review considers some of the clinical benefits associated with using stereochemically pure drugs in psychiatric conditions other than depression. A review of the evidence shows that enantiomers offer four main benefits. Firstly, using a single enantiomer may allow a reduction in total dose, while maintaining or improving outcomes. For example, (+)-nefopam's antinociceptive activity is greater than that produced by both the racemate and (,)-nefopam, but with the same level of acute toxicity. Thus, a single enantiomer may offer greater efficacy, dose for dose, than the racemate. Secondly, assessing dose,response relationships is simpler. There is no reason to suppose that a racemate will necessarily contain the isomers' optimum therapeutic ratio, that one of the isomers will be inactive or that the enantiomers' dose,response curves will coincide. For example, the dose,response relationship for the induction of catalepsy in the rat by thioridazine suggested that the racemate was around 12 times more potent than (+)-thioridazine and three times more potent than (,)-thioridazine, when considering the actual concentrations in the striatum. Thirdly, using a single enantiomer may reduce pharmacokinetic and pharmacodynamic variability between patients. For example, the coefficients of variation for some of methadone's pharmacokinetic parameters may reach 70%, which might have clinical consequences. Finally, using a single enantiomer may reduce toxicity arising from the therapeutically inactive stereoisomer. For example, the single enantiomers of bupivacaine and ropivacaine are significantly less cardiotoxic than their respective racemates. This review illustrates why stereochemistry should be considered when assessing the toxicology, pharmacokinetics, metabolism and efficacy of a racemate. Indeed, the differences may be so marked that achiral analyses may be misleading, and clinicians should consider prescribing an enantiomer whenever possible. In many cases, prescribing a single enantiomer improves the benefit:risk ratio. Finally, there is no reason to suppose that a racemate's characteristics will apply to the constituent enantiomers. Copyright © 2001 John Wiley & Sons, Ltd. [source]

Past expectations, present disappointments, future hopes or psychopathology as the rate-limiting step of progress in psychopharmacology

HUMAN PSYCHOPHARMACOLOGY: CLINICAL AND EXPERIMENTAL, Issue 1 2001
H. M Van Praag
Abstract In 1974 I published a paper in which we predicted that biological depression research would lead to new, innovative antidepressants, to more sophisticated prescription of antidepressants and ultimately to ,functional psychopharmacology'. These expectations have not materialized. The reasons why are discussed and the conclusion is reached that there are reasons to believe that, belated, they will come true. I consider it no bold venture to uphold them. Copyright © 2001 John Wiley & sons, Ltd. [source]

Psychodynamic and Neurological Perspectives on ADHD: Exploring Strategies for Defining a Phenomenon

JOURNAL FOR THE THEORY OF SOCIAL BEHAVIOUR, Issue 4 2001
Adam Rafalovich
This article is a discourse analysis of two historical inquiries into what clinici-ans today call attention deficit hyperactivity disorder (ADHD). Of primary con-cern in this regard are psychodynamic perspectives towards ADHD symptoms, championed by psychoanalysts and psychologists, and neurological perspectives towards ADHD, which continue to favor a purely physiological approach to understanding the disorder. Those within the psychodynamic camp are inclined to view ADHD as an interactional difficulty between self and social environment - a condition best remedied by psychotherapy. Those within the neurological camp see ADHD as a specific brain process, whose effective treatment depends upon adequate psychopharmacology. This essay argues that both psychodynamic and neurological perspectives towards ADHD have strategized to legitimate one perspective through the expulsion of the other. Within the current era of ADHD nomenclature and treatment it is clear that neurological perspectives dominate the debate. However, neurological perspectives continue to be haunted by a considerable amount of skepticism, both nationally and internationally. Because of this it would be difficult to assert that neurological perspectives, though winning the "legitimation race" in contemporary understandings of ADHD, are entirely monolithic sources of ADHD knowledge. [source]

Training psychologists in clinical psychopharmacology

JOURNAL OF CLINICAL PSYCHOLOGY, Issue 6 2002
Ronald F. Levant
This article first describes three types of psychopharmacology training programs for psychologists: 1. postdoctoral programs that award certificates and/or continuing education credit; 2. postdoctoral programs that award master's degrees in psychopharmacology; 3. a predoctoral program that awards joint psychology and nursing degrees. Next, the postdoctoral masters degree program at Nova Southeastern University is described in some detail. We close with some general comments about the current status of these training efforts. © 2002 Wiley Periodicals, Inc. J Clin Psychol 58: 611,615, 2002. [source]

The psychologist's role in the collaborative process of psychopharmacology

JOURNAL OF CLINICAL PSYCHOLOGY, Issue 6 2002
Kenneth A. Weene
This is a discussion of a collaborative approach between psychologists, physicians, patients, and others in the administration of psychotropic medication. It is based on a systems point of view. In that perspective, not only are the people indicated above a system, but also the patient is considered from a holistic-systems point of view. It requires that the psychologist not only be a member of the system, and a well-versed in medication member at that; (s)he must also be an observer of the system, be able to take a meta perspective, in order to be able to exercise some unique functions,functions for which psychologists are well-trained. © 2002 Wiley Periodicals, Inc. J Clin Psychol 58: 617,621, 2002. [source]

On the Difference Between Designing Children and Raising Them: Ethics and the Use of Educationally Oriented Biotechnology

MIND, BRAIN, AND EDUCATION, Issue 2 2010
Zachary Stein
The use of educationally oriented biotechnology has grown drastically in recent decades and is likely to continue to grow. Advances in both the neurosciences and genetics have opened up important areas of application and industry, from psychopharmacology to gene-chip technologies. This article reviews the current state of educationally oriented biological technologies, eventually focusing on the use of psychiatric drugs with children and adolescents to improve their academic performance. Distinguishing between "good" and "bad" uses of biological technologies is complicated by conflicting theoretical views about human development, the etiology of disability, and the diagnostic categories that structure treatments. To address these issues I introduce a set of ethical concepts, which are based on a biopsychosocial approach to human development. The difference between designing children and raising children marks an ethically salient difference between approaches that focus on only part of the child (e.g., her brain) and approaches that focus on the full biopsychosocial complexity of the developing child in context. This clarifies the importance of the child's right to both autonomy and care. Implications for policy and practice are offered. [source]

Strategies Used by Advanced Practice Psychiatric Nurses in Treating Adults With Depression

PERSPECTIVES IN PSYCHIATRIC CARE, Issue 4 2008
Evelyn Parrish APPN
PURPOSE.,Strategies used by psychiatric advanced practice registered nurses (APRNs) in treating clients with depression are described to explore their effectiveness. DESIGN AND METHODS.,Ten APRNs participated in semistructured individual interviews for this qualitative descriptive study. The use of either a symptom severity scale or symptom reduction checklist was used to measure the effectiveness of the strategies used. FINDINGS.,APRNs identified a biopsychosocial approach as the primary component of their treatment of clients with depression. Other strategies identified include psychopharmacology, cognitive-behavioral therapy, and partnering with the client. PRACTICE IMPLICATIONS.,Treatment of depression can be enhanced with the incorporation of the biopsychosocial strategies along with standard treatment modalities. [source]

Psychogeriatric Research: A Conceptual Introduction to Aging and Geriatric Neuroscience

PSYCHOGERIATRICS, Issue 3 2001
Ramón Cacabelos
Abstract: Psychogeriatrics (PG) is a multidisciplinary specialty in clinical neuroscience dealing with brain disorders in the elderly population. As any other biomedical field PG has to establish an educational and practical framework in epidemiology, etiopathogenesis, diagnosis, treatment, and social, ethical, and legal issues associated with brain aging and age-related central nervous system disorders. Understanding the molecular basis of aging will help to characterize and differentiate the fundamentals of pathological aging and psychogeriatric ailments. Modern epidemiology of age-related brain disorders have to incorporate novel diagnostic criteria, biological markers, and genetic epidemiology to its methodological armamentarium to avoid bias. Molecular genetics will help to conceptually redefine many psychogeriatric disorders depending upon its genetic component and those interacting environmental factors leading to the phenotypic expression of given diseases. Genetic testing for monogenic and complex/polygenic/multifactorials disorders has to be included in diagnostic protocols since approximately 60 to 80% of major psychogeriatric disorders are genetically driven. It is also important to distinguish mutational genetics from susceptibility genetics in order to establish novel therapeutic strategies and preventive programmes. Genomics, proteomics, and pharmacogenomics are novel fields from which PG can benefit in the areas of etiopathogenesis, diagnosis, and treatment. Drug development in PG requires updated regulations in developed countries. New pharmacological treatments for aging brain disorders are needed. Pharmacogenomics will become an optimal strategy for drug development, contributing to design a molecular psychopharmacology for the elderly, individualizing drug therapy, optimizing efficacy and safety, and reducing unnecessary costs. [source]

The therapist's guide to psychopharmacology: working with patients, families, and physicians to optimize care.

PSYCHO-ONCOLOGY, Issue 2 2008
A. Ari Albala, Edited by JoEllen Patterson, Margaret E. McCahill, Todd M. Edwards.
No abstract is available for this article. [source]